SUBSCRIBE
SUBSCRIBE

FDA Okays First Subcutaneous HAE Drug

December 3, 2009 | 
1 min read
MedPage Today -- The FDA has approved ecallantide (Kalbitor), the first subcutaneous treatment for acute hereditary angioedema (HAE) attacks, for patients 16 and older.